When initial therapy proves insufficient, treatment escalation includes: Biologic DMARDs targeting specific inflammatory pathways (TNF inhibitors, IL-6 inhibitors, T-cell costimulation blockers, B-cell depleting agents) Targeted synthetic DMARDs such as JAK inhibitors (tofacitinib, baricitinib, upadacitinib), which carry FDA boxed warnings for serious cardiovascular events, malignancy, and thrombosis [24] [25] Combination DMARD therapy Short-term glucocorticoids for symptom control during treatment initiation Before starting biologic or targeted synthetic DMARDs, screening for tuberculosis and hepatitis B is recommended, along with appropriate vaccinations according to ACR guidelines
Companies that sell compounded medications should disclose that these drugs are not FDA-approved and haven't undergone the same rigorous testing for safety and effectiveness as FDA-approved drugs
It's a bureaucratic nightmare by design
Early investigations indicated that incubating dermal fibroblasts with nanomolar concentrations of GHK-Cu may have increased the synthesis of collagen, elastin, glycosaminoglycans (GAGs), and small proteoglycans such as decorin
Expert insights, shocking footage, and real stories
